ImmunityBio Inc
IBRX
ISIN US45256X1037 / Valor 110468647
ImmunityBio Inc
UMushroom community rating:
About company
ImmunityBio Inc is a biotechnology company that focuses on developing comprehensive immunotherapy approaches to target various types of cancer and infectious diseases. The company's platforms aim to activate different components of the immune system, such as natural killer cells, T cells, and macrophages, to establish immune memory and trigger an effective anti-tumor immune response. ImmunityBio is currently conducting clinical trials to assess the safety and efficacy of their therapies and personalized vaccine candidates across multiple tumor types. The company has secured significant funding for commercialization and pipeline expansion efforts, with a focus on potential regulatory approval for their bladder cancer treatment N-803. Additionally, ImmunityBio is collaborating with the National Cancer Institute on a study for Lynch syndrome cancer prevention.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2312 M
Market cap (USD)
1,363,515
Daily traded volume (Shares)
3.62 / 3.295
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
